Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
Amgen (AMGN) is primarily focused on six therapeutic areas: oncology/hematology, cardiovascular, inflammation, bone health, neuroscience, and nephrology.
YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.
Amgen’s top-line growth is under pressure following the rising competition for key drug Enbrel, which had a 26% share in Amgen’s total product sales in 3Q16.
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
With the Express Scripts agreement, Horizon Pharma’s net sales in 2017 are expected to rise. The probability of a top-line expansion has boosted investor sentiment.
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.
Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.
Pfizer’s avelumab seems to be its potential growth driver for the next one to five years. Pfizer is developing the product with its partner Merck KGaA.
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.
When compared with its estimated $30.2 billion total revenue for 2016, Gilead Sciences’s (GILD) $99 billion market capitalization on November 23 seemed to be at a greater discount. GILD had a forward PE ratio of ~7.0x against its peers’ average PE of ~12.1x.
Trump’s healthcare agenda During his campaign, Trump came up with a seven-point plan for the healthcare industry. In this plan, he proposed to repeal the Affordable Care Act. Although a complete repeal doesn’t seem feasible, if applied, it would definitely take a toll on hospitals and insurance companies. In the next article, we’ll discuss the severity of […]
The effects of repealing Obamacare Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it with another policy, the hospital sector fell on November 9, the day after the election. Trump believes that providing healthcare facilities to illegal immigrants costs […]
Valeant Pharmaceuticals (VRX) announced its 3Q16 earnings on November 8. On a GAAP basis, Valeant reported a loss of ~$1.2 billion, which reflects a loss of $3.49 per diluted share during the period.
The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.
With the sale of Salix, Valeant’s adjusted revenues will fall 14.0%. Since Salix is a high-margin business, the sale will adversely impact Valeant’s margins.
Novo Nordisk’s (NVO) diabetes and obesity care portfolio consists of modern insulin, Victoza, human insulin, new generation insulin, and other diabetes and obesity care products.
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.
Roche Holding (RHHBY) reported earnings for 3Q16 on October 20, 2016. Wall Street analysts expected Roche to report 12.6 billion Swiss francs in revenue during 3Q16 while the company reported ~12.5 billion Swiss francs.
Following analysts’ projections, Soliris revenues in 3Q16 and 4Q16 should rise 9.0% and 10.0%, respectively, YoY to reach $725.9 million and $760.6 million, respectively.
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.
Over the past two years, Pfizer hasn’t really offered lucrative returns to shareholders. The stock rose 13% from October 10, 2014, to October 11, 2016.
Like other big pharmaceutical companies, Pfizer witnessed negative top line growth. With multiple acquisitions recently, it’s poised to grow its top line.
With Bristol-Myers Squibb’s (BMY) Opdivo being the standard of care in the second-line lung cancer space, it faces cutthroat competition from Merck’s (MRK) Keytruda.
CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]
Bristol-Myers Squibb’s valuation On October 5, 2016, Bristol-Myers Squibb (BMY) was trading at 12.98x its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple. The valuation multiple was quite close to that of Eli Lilly and Company (LLY), which was trading at 13.04x its forward EBITDA. Peers Celgene (CELG), Roche (RHHBY), […]
BioMarin’s (BMRN) early-stage pipeline includes BMN-270, a gene therapy program for hemophilia A and vosoritide, which is indicated for achondroplasia.
The Bloomberg consensus of 24 brokerage firms shows that 66.7% brokerage firms recommend Vertex as a “buy,” while 33.3% analyst issued a “hold” ratings.
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
On September 20, 2016, Gilead Sciences (GILD) was trading at a forward PE (price-to-earnings) multiple of 7.14x, which was at a discount compared to its peers.
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
According to the September 12, 2016, agreement between Horizon Pharma (HZNP) and Raptor Pharmaceuticals, HZNP will acquire Raptor common stock at $9 per share.
Sanofi’s Specialty Care franchise consists of rare disease drugs, MS (multiple sclerosis) drugs, and oncology drugs and generated ~$3.3 billion in 1H16.
During the second quarter of 2016, Sanofi’s aggregate sales declined by 0.2% to about $10 billion. Its diabetes and cardiovascular franchise fell by 2%.
